Ellicott City, MD – The Society for Clinical Research Sites (SCRS) and the National Association of Veterans’ Research and Education Foundations (NAVREF) are pleased to announce an alliance between the two organizations. This relationship will provide SCRS membership, mentoring and training, and other elements to NAVREF members. NAVREF is the nonprofit research and education association with 80 member sites affiliated with Department of Veterans Affairs medical centers. “Research sites associated with Department of Veterans Affairs medical centers have not always had an easy time making a good fit with industry-sponsored clinical trials,” said Christine Pierre, President of SCRS. “We are dedicated to assisting NAVREF establish VA associated research sites as first in class sites enabling them to offer clinical research opportunities to our veterans and their families.” “We are thrilled to be joining forces with SCRS,” said Rick Starrs, CEO of NAVREF. “Our nonprofit foundations and the VA have been actively working to deliver more clinical research studies to veterans. This partnership with SCRS will bring NAVREF closer to achieving our vision of a nation in which veterans receive the finest care based on innovative research and education.” About SCRS SCRS is a global trade organization founded in 2012 which represents over 3,000 research sites in 49 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About NAVREF Formed in 1992, the National Association of Veterans' Research and Education Foundations (NAVREF) is the 501(c)(3) nonprofit membership organization of research and education foundations affiliated with Department of Veterans Affairs (VA) medical centers. These nonprofits, also known as the VA-affiliated nonprofit research and education corporations (NPCs) are authorized by Congress to provide flexible funding mechanisms for the conduct of research and education at VA facilities nationwide. Currently, NAVREF has 80 members. Visit navref.org.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
2 Commerce Drive
Cranbury, NJ 08512